调脂治疗对2型糖尿病伴脂代谢异常患者早期胰岛素分泌改善作用的研究  

Improvable effect of lipid-lowering treatment on early insulin secretion in T2DM patients with dyslipidemia

作　　者：田景伦 周仕龙[1] 王小红[1] 贺奕[1] 陈德才[2] 

机构地区：[1]成都市温江区人民医院内分泌科,611130 [2]四川大学华西医院内分泌科

出　　处：《中国糖尿病杂志》2013年第4期312-314,共3页Chinese Journal of Diabetes

基　　金：四川省卫生厅科研项目(110116)

摘　　要：目的探讨调脂治疗对T2DM伴脂代谢异常患者早期胰岛素分泌功能的影响。方法纳入71例新诊断T2DM伴脂代谢异常患者为治疗组,根据不同血脂水平,予辛伐他汀和(或)非诺贝特治疗12周;另选血脂正常的新诊断T2DM患者32例作为对照组,两组均接受降糖治疗,且血糖控制均达标。分别在0、6和12周行OGTT,计算早期胰岛素分泌指数ΔI30/ΔG30。结果治疗后两组ΔI30/ΔG30均有升高的趋势,且治疗组升高程度高于对照组(P<0.05)。结论在一定时期内,调脂治疗对新诊断T2DM伴脂代谢异常患者早期胰岛素分泌功能具有改善作用。Objective To investigate the improvable effect of lipid-lowering treatment on early insulin secretion in T2DM patients with dyslipidemia. Methods Seventy-one newly diagnosed T2DM patients accompanied with dyslipidemia （treatment group） accepted simvastatin or/and fenofibrate therapy according to their different lipid fractions for 12 weeks, and the 32 newly diagnosed T2DM patients without dyslipidemia （control group） received the lipid-lowering treatment. Both groups accepted anti- hyperglycemic treatment and their glucose control got the target. The OGTT was given in the 0, 6 and 12 weeks for calculating the early insulin secretion indexes △I30/△G30. Results After treatment, the indexes △I30/△G30 of both groups had an increasing trend, and the increasing degree was higher in the treatment group than in control group. （P〈0. 05）. Conclusion In a certain period of time, the lipid- lowering treatment improves the early insulin secretion of the newly diagnosed T2DM patients with dyslipidemia.

关 键 词：糖尿病 2型 脂代谢异常 降血治疗 

分 类 号：R587.1[医药卫生—内分泌] R589[医药卫生—内科学]